Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer

British Journal of Urology(2021)10.1111/bju.15603Source: DataRank Database

Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer is a research paper published in British Journal of Urology (2021). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.81)OA: bronzeTopics (69)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (47)

Rafee Talukder ORCID,Leonidas Nikolaos Diamantopoulos ORCID,Lucía Carril-Ajuria ORCID,Daniel Castellano ORCID,Ivan de Kouchkovsky ORCID

Live enrichment

PubMed:34597472 PMC:PMC10257152 OpenAlex:https://openalex.org/W3203689165

National Cancer Research Institute

Grant: T32CA009515

National Center for Advancing Translational Sciences

Grant: UL1 TR002319

NCI NIH HHS

Grant: P30 CA023100

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 3UL1TR002319-02S1

Transform Dissemination and Implementation Science in CTSA Programs

National Institutes of Health

Grant: 5T32CA009515-05

TRAINING IN CANCER BIOLOGY AND MARROW TRANSPLANTATION

Wellcome Trust

FWCI

0.81

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

bronzeLicense: Wiley Online Library User Agreement

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bju.15603

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bju.15603

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15603

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/bju.15603

publisherhttps://bjui-journals.onlinelibrary.wiley.com/doi/pdf/10.1111/bju.15603

Fields of Study

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis03 medical and health sciences0302 clinical medicineHumansImmune Checkpoint InhibitorsRetrospective StudiesCarcinoma, Transitional CellUrinary Bladder NeoplasmsB7-H1 Antigen

MeSH Terms

Immune Checkpoint InhibitorsUrinary Bladder NeoplasmsCarcinoma, Transitional CellHumansRetrospective StudiesB7-H1 Antigen

Keywords

Urothelial cancerCancerOncologyAssociation (psychology)MedicineCancer therapyInternal medicineBladder cancerCancer researchPsychologyPsychotherapistImmunotherapyUrothelial CarcinomaOutcomesImmune Checkpoint Inhibitors#Bladdercancer#Blcsm#Uroonc#UtucUrinary Tract NeoplasmsRetrospective Studies (mesh)Clinical SciencesOncology and CarcinogenesisRadiation Oncology (rcdc)610Transitional Cell (mesh)B7-H1 AntigenHealth Sciences1103 Clinical Sciences (for)3211 Oncology and carcinogenesis (for-2020)HumansUrology & Nephrology (science-metrix)32 Biomedical and Clinical Sciences (for-2020)3202 Clinical Sciences (for-2020)Retrospective StudiesCancer (rcdc)Humans (mesh)Carcinoma, Transitional Cell6.1 Pharmaceuticals (hrcs-rac)3 Good Health and Well Being (sdg)Biomedical and Clinical SciencesImmune Checkpoint Inhibitors (mesh)CarcinomaCancer (hrcs-hc)Urology & NephrologyGood Health and Well BeingUrinary Bladder Neoplasms6.1 PharmaceuticalsInternal Medicine and SpecialtiesRadiation OncologyTransitional CellUrinary Bladder Neoplasms (mesh)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being